Microvascular Angina
Conditions
Brief summary
Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease
Detailed description
The investigators will select consecutive patients who experienced chest pain but had no significant coronary artery stenosis (\<50% stenosis). Coronary microvascular function will be evaluated by adenosine stress echocardiography. Coronary blood flow velocities will be measured at 1, 2, and 3 min after adenosine infusion. Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed.
Interventions
DIAGNOSTIC_TESTAdenosine stress echocardiography
Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood flow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel flow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary flow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
Sponsors
Korea University Anam Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Typical/atypical chest pain or ischemic symptoms including dyspnea * No significant coronary artery stenosis (\<50% stenosis) in coronary angiography or computed tomography
Exclusion criteria
* ≥ Moderate valvular heart disease * Congenital heart disease * Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis * Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension * Receiving anticancer drugs * Vasculitis associated with autoimmune diseases * Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A composite outcome including all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure | 1 year | Number of participants with a composite outcome including all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure |
Countries
South Korea
Contacts
Primary ContactSo Ree Kim, PhD
Outcome results
None listed